Structural, Spectroscopic (NMR, IR, and Raman), and DFT Investigation of the Self-Assembled Nanostructure of Pravastatin-LDH (Layered Double Hydroxides) Systems
Source abstract
Abstract
Layered double hydroxide (LDH) nanocontainers, suitable as carriers for anionic drugs, were intercalated with Pravastatin drug using magnesium–aluminum and zinc–aluminum in a M II /Al molar ratio equal 2 and different Al 3+ /Pravastatin molar ratios. Postsynthesis treatments were used in order to increase the materials crystallinity. Hybrid materials were characterized by a set of physical chemical techniques: chemical elemental analysis, X-ray diffraction (XRD), mass coupled thermal analyses, vibrational infrared and Raman spectroscopies, and solid-state 13 C nuclear magnetic resonance (NMR). Results were interpreted in light of computational density functional theory (DFT) calculations performed for Sodium Pravastatin in order to assign the data obtained for the LDH intercalated materials. XRD peaks of LDH-Pravastatin material and the one-dimensional (1D) electron density map pointed out to a bilayer arrangement of Pravastatin in the interlayer region, where its associated carboxylate and vicinal hydroxyl groups are close to the positive LDH. The structural organization observed for the stacked assembly containing the unsymmetrical and bulky monoanion Pravastatin and LDH seems to be promoted by a self-assembling process, in which local interactions are maximized and chloride ion cointercalation is required. It is observed a high similarity among vibrational and 13 C NMR spectra of Na-Pravastatin and LDH-Pravastatin materials. Those features indicate that the intercalation preserves the drug structural integrity. Spectroscopic techniques corroborate the nature of the guest species and their arrangement between the inorganic layers. Changes related to carboxylate, alcohol, and olefinic moieties are observed in both vibrational Raman and 13 C NMR spectra after the drug intercalation. Thus, Pravastatin ions are forced to be arranged as head to tail through intermolecular hydrogen bonding between adjacent organic species. The thermal decomposition profile of the hybrid samples is distinct of that one observed for Na-Pravastatin salt, however, with no visible increase in the thermal behavior when the organic anion is sequestrated within LDH gap.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Layered Double Hydroxides Synthesis and Applications · Polyoxometalates: Synthesis and Applications · Inorganic Chemistry and Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Departamento de Química Fundamental, Instituto de Química, Universidade de São Paulo, C. P. 26077, CEP 05513-970, São Paulo - SP, Brazil
Departamento de Física de Materiais e Mecânica, Instituto de Física, Universidade de São Paulo, C. P. 66318, CEP 05315-970, São Paulo - SP, Brazil
Clermont Université, Université Blaise Pascal, Institut de Chimie de Clermont-Ferrand, BP 10448, F-63000 Clermont-Ferrand, France
CNRS, UMR 6296, ICCF, BP 80026, F-63171 Aubière, France
References (61)
Show source-provided references
1. Carretero M. I. · Appl. Clay Sci. · 2010 · 47 · 17110.1016/j.clay.2009.10.016 ↗
2. Oh J.-M. · J. Mater. Chem. · 2009 · 19 · 255310.1039/b819094a ↗
3. Cunha V. R. R. · Quim. Nova · 2010 · 33 · 15910.1590/S0100-40422010000100029 ↗
4. Oh J.-M. · Adv. Funct. Mater. · 2009 · 19 · 161710.1002/adfm.200801127 ↗
5. Costantino U. · Z. Kristallogr. · 2009 · 224 · 27310.1524/zkri.2009.1153 ↗
6. Ladewig K. · Expert Opin. Drug Deliv. · 2009 · 6 · 90710.1517/17425240903130585 ↗
7. Khan A. I. · Ind. Eng. Chem. Res. · 2009 · 48 · 1019610.1021/ie9012612 ↗
8. Desigaux L. · Nano Lett. · 2006 · 6 · 19910.1021/nl052020a ↗
9. Leroux F · J. Mater. Chem. · 2005 · 15 · 362810.1039/b505014f ↗
10. hO’Hare, D. M.,Drug delivery system comprising a drug intercalated between a Layered Double Hydroxide, WO 0247729, 2002;
11. iPark, T.; Choy, J. H.; Oh, J. M.; Jung, J. S.,Injectable drug carrier comprising Layered Double Hydroxide, WO 2006/129893, 2006.
12. jMarenzi, G.; Bolognese, A.; Califano, L.; Calignano, A.; Costantino, U.; Sammartino, G.; Vittoria, V.,Controlled-delivery system of pharmacologically active substances, preparation process and medical use thereof, WO 2007/010584, 2007.
13. Trifirò F. · 1996
14. Braterman P. S. · 2004
15. Cavani F. · Catal. Today · 1991 · 11 · 17310.1016/0920-5861(91)80068-K ↗
16. Vaccari A. · Catal. Today · 1998 · 41 · 5310.1016/S0920-5861(98)00038-8 ↗
17. Faraji A. H. · Bioorg. Med. Chem. · 2009 · 17 · 295010.1016/j.bmc.2009.02.043 ↗
18. Davignon J. · Circulation · 2004 · 109 · 39
19. Corsini A. · Pharmacol. Therapeut · 1999 · 84 · 41310.1016/S0163-7258(99)00045-5 ↗
20. Campo V. L. · Quim. Nova · 2007 · 30 · 42510.1590/S0100-40422007000200033 ↗
21. Dinarello C. A. · Cell · 2010 · 140 · 93510.1016/j.cell.2010.02.043 ↗
22. Barrios-González J. · Appl. Microbiol. Biotechnol. · 2010 · 85 · 86910.1007/s00253-009-2239-6 ↗
23. Tousoulis D. · Atherosclerosis · 2008 · 201 · 23610.1016/j.atherosclerosis.2008.05.034 ↗
24. Jain M. K. · Nat. Rev. · 2005 · 4 · 977
25. Manzoni M. · Appl. Microbiol. Biotechnol. · 2002 · 58 · 55510.1007/s00253-002-0932-9 ↗
26. Triscari J. · J. Clin. Pharmacol. · 1995 · 35 · 14210.1002/j.1552-4604.1995.tb05002.x ↗
27. Jacobsen W. · Drug Metab. Dispos. · 1999 · 27 · 17310.1016/S0090-9556(24)15273-7 ↗
28. Hatanaka T. · Clin. Pharmacokinet. · 2000 · 39 · 39710.2165/00003088-200039060-00002 ↗
29. aKumar, M; Talwar, N.; Raghuvanshi, R. S.; Rampal, A. K.Controlled Release Drug Delivery System of Pravastatin, U.S. Patent 2005/0089572 A1.
30. bHabib, Y. S.; Ullah, I.; Jain, N. B.Enteric Coated Pravastatin Bead Formulation. WO 00/33821.
31. Moghadasian M. H. · Life Sci. · 1999 · 65 · 132910.1016/S0024-3205(99)00199-X ↗
32. Shidhaye S. S. · AAPS PharmSciTech. · 2010 · 11 · 41610.1208/s12249-010-9381-4 ↗
33. Garg Y. · AAPS PharmSciTech. · 2011 · 12 · 67310.1208/s12249-011-9626-x ↗
34. Broz P. · J Cardiovasc. Pharmacol. · 2008 · 51 · 24610.1097/FJC.0b013e3181624aed ↗
35. Coimbra M · J. Controlled Release · 2010 · 148 · 30310.1016/j.jconrel.2010.09.011 ↗
36. Harisa G. E. I. · Int. J. Med. Sci. · 2011 · 8 · 22210.7150/ijms.8.222 ↗
37. Panda H. S. · J. Phys. Chem. B · 2009 · 113 · 1509010.1021/jp905440e ↗
38. Constantino V. R. L. · Inorg. Chem. · 1995 · 34 · 88310.1021/ic00108a020 ↗
39. Whittingham M. · 1982
40. Lee C. T. · Phys. Rev. B · 1988 · 37 · 78510.1103/PhysRevB.37.785 ↗
41. Becke A. D. · J. Chem. Phys. · 1996 · 104 · 104010.1063/1.470829 ↗
42. Frisch M. J. · 2003
43. Sato S. · J. Antibiot. · 1988 · 41 · 126510.7164/antibiotics.41.1265 ↗
44. Wolinski K. · J. Am. Chem. Soc. · 1990 · 112 · 825110.1021/ja00179a005 ↗
45. Cheeseman J. R. · J. Chem. Phys. · 1996 · 104 · 549710.1063/1.471789 ↗
46. Casabianca L. B. · J. Chem. Phys. · 2008 · 128 · 05220110.1063/1.2816784 ↗
47. Halls M. D · J. Chem. Phys. · 1999 · 111 · 881910.1063/1.480228 ↗
48. Scott A. P. · J. Phys. Chem. · 1996 · 100 · 1650210.1021/jp960976r ↗
49. Keri, V.; Arvai, E. N.; Czovek, Z.; Kovacsne-Mezei, A.; Katai, I. V.; Racz, C. N.Methods of making Pravastatin sodium, Patent U.S. 2006 194984A1.
50. Bauer J. · Adv. Funct. Mater. · 2003 · 13 · 24110.1002/adfm.200390036 ↗
51. Pisson J. · Chem. Mater. · 2011 · 23 · 148210.1021/cm1030848 ↗
52. Costantino U. · Langmuir · 1999 · 15 · 445410.1021/la981672u ↗
53. Martín-Islán A. P. · J. Phys. Chem. B · 2006 · 110 · 2614810.1021/jp0624449 ↗
54. Bacher M. · Magn. Reson. Chem. · 2009 · 47 · 7110.1002/mrc.2312 ↗
55. Andersson M. P · J. Phys. Chem. A · 2005 · 109 · 293710.1021/jp045733a ↗
56. Dollish F. R. · 1974
57. Nakamoto K. · 1997
58. Gordijo C. R. · J. Pharm. Sci. · 2005 · 94 · 113510.1002/jps.20336 ↗
59. de Faria D. L. A. · J. Raman Spectrosc. · 1998 · 29 · 10310.1002/(SICI)1097-4555(199802)29:2<103::AID-JRS199>3.0.CO;2-J ↗
60. Pereira D. C. · J. Brazilian Chem. Soc. · 2006 · 17 · 165110.1590/S0103-50532006000800024 ↗
61. Kloprogge J. T. · J. Raman Spectrosc. · 2004 · 35 · 96710.1002/jrs.1244 ↗